VIDAC PHARMA LTD has a total of 22 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2017. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and China. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and micro-structure and nano-technology are BEIJING HASANLIAN SCIENCE & TECH CO LTD, NEONC TECH INC and ANHUI YIXINMING PHARMACEUTICAL TECH CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 6 | |
#2 | WIPO (World Intellectual Property Organization) | 5 | |
#3 | China | 3 | |
#4 | EPO (European Patent Office) | 3 | |
#5 | Australia | 2 | |
#6 | Canada | 2 | |
#7 | Brazil | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Micro-structure and nano-technology | |
#4 | Biotechnology |
# | Name | Total Patents |
---|---|---|
#1 | Becker Oren Menahem | 21 |
#2 | Salama Paul | 15 |
#3 | Behar Vered | 11 |
#4 | Yosef Hamo Reut | 6 |
#5 | Mann Brickman Chaim | 6 |
#6 | Dor-On Eyal | 3 |
#7 | Pahima Hadas Tamar | 3 |
#8 | Paul Salama | 1 |
#9 | Oren Menahem Becker | 1 |
#10 | Chaim Mann Brickman | 1 |
Publication | Filing date | Title |
---|---|---|
CN111556861A | Preparation method of jasmonate compound | |
WO2018083705A1 | Use of hexokinase 2/mitochondria-detaching compounds for treating hexokinase-2 (hk2)-expressing cancers | |
US2018303819A1 | Use of hexokinase 2/mitochondria-detaching compounds for activating immune responses | |
US2020031815A1 | Piperazine derivatives, pharmaceutical compositions and methods of use thereof | |
US2020297620A1 | Stable pharmaceutical compositions for topical administration and uses thereof |